Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio to Participate in the Leerink Partners Global Biopharma Conference
04:05pm, Tuesday, 05'th Mar 2024
SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
10:55am, Tuesday, 05'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positiv
89BIO (ETNB) Just Overtook the 200-Day Moving Average
10:31am, Tuesday, 05'th Mar 2024
After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 200-day moving average, suggesting a long-term bullish
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
04:05pm, Thursday, 29'th Feb 2024
– Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively –
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 06'th Feb 2024
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 05'th Feb 2024
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
10:38am, Thursday, 18'th Jan 2024
After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 20-day moving average, suggesting a short-term bullish
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?
11:19am, Wednesday, 10'th Jan 2024
The mean of analysts' price targets for 89BIO (ETNB) points to a 168.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
89bio: Despite Peer Trial Setback, Potential Remains In NASH
06:59pm, Wednesday, 06'th Dec 2023
89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibr
89bio's Low Price Presents An Opportunity
02:15pm, Thursday, 26'th Oct 2023
89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive with excellent phase 2 data and strong financials.
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
08:00am, Tuesday, 17'th Oct 2023
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
Why Shares of 89bio Plummeted on Tuesday
04:13pm, Tuesday, 10'th Oct 2023
89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases.
89bio to Participate in the 2023 Cantor Global Healthcare Conference
08:00am, Wednesday, 20'th Sep 2023
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Tuesday, 05'th Sep 2023
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic
03:01pm, Monday, 28'th Aug 2023
Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from the biotechnology company's current share price of
